The chondroxide tablets area drug designed to stimulate the regeneration of cartilaginous tissue. This drug also has analgesic and anti-inflammatory effects.
Tablets "Chondroxide" create the maximumconcentration in the plasma when administered orally once through 34 hours, and after 45 hours in the synovial fluid. It should be noted that this preparation accumulates almost completely in the cartilaginous tissue, and for its penetration into the joint cavity the synovial membrane is not an obstacle. Throughout the day it is excreted by the kidneys.
In its composition tablets "Chondroxide" contain0.25 grams of dry substance chondroitin sulfate (active ingredient), as well as auxiliary - calcium stearate, crospovidone, polyvinylpyrrolidone (povidone), MCC, and a sufficient amount of basic water magnesium carbonate (magnesium carbonate).
This drug providesthe construction of a basis of bone and cartilaginous tissue, also affects the metabolic processes in fibrous and hyaline cartilage. In addition, the tablets "Chondroxide" provide inhibition of the destruction of connective and cartilaginous tissues, inhibiting enzymes that damage the cartilaginous tissue.
Obstruction of compression of connective tissue anda kind of lubrication of the surfaces of the joint - all this provides "Chondroxide". Tablets reviews are positive, as they also stimulate the synthesis of glycosaminoglycans, and increase the production of intra-articular fluid, and provide regeneration of the cartilaginous articular surfaces and articular bag, which reduces inflammation, increases the mobility of joints altered by the pathological process, and also reduces tenderness in walking and even in alone.
Has potential properties thatprevent the formation of thrombi from fibrin in the subchondral and synovial microcirculatory bed. An important property is a slowdown in its application of the progression of osteochondrosis and osteoarthrosis. When using "Chondroxide", the metabolism in the articular cartilage is normalized, which also stimulates its regeneration. A characteristic feature of this drug is the preservation of the achieved therapeutic effect for a long time after the end of its use.
«Хондроксид» показан к применению при развитии degenerative-dystrophic diseases of the spine and joints, including osteochondrosis and osteoarthritis of the spine (both for prevention and for treatment).
Contraindications for its use are the following conditions:
Caution should be given to patients with bleeding and a tendency to bleeding in an anamnesis.
In pregnancy, its use is categorically contraindicated. During lactation during the course of therapy, it is necessary to stop breastfeeding.
When using "Hondroksida" may develop allergic reactions, nausea, diarrhea. If an allergy occurs, you must cancel Hondroxide.
Instructions
Tablets must be taken orally, washed downa small amount of liquid. 2 times a day for 0.5 grams. The duration of the initial course of its application should be six months. After the withdrawal of "Chondroxide", its therapeutic effect persists for approximately 3 years (depending on the stage of the disease and its localization). If necessary, it is possible to conduct repeated courses, their duration is determined on an individual basis.
Please note, this drug may enhance the pharmacological action of fibrinolytics, anticoagulants and antiplatelet agents.